The analysis of the dataset of Prat, A., et al. revealed that three out of six significant drug targets—FCGR2B, IGF1R, and KIT—substantially increased the odds of having stable disease versus progressive disease in EGFR WT cancer patients. The gene discussed is FCGR2B; the disease is cancer.